CURE spoke with incoming ASCO president Dr. Deb Schrag on elevating the patient voice, humanism in care and why partnership shapes better cancer outcomes. Dr. Deb Schrag knows all about the importance ...
Adjuvant therapy with Imfinzi (durvalumab) and Imjudo (tremelimumab-actl) in patients with resected renal cell carcinoma was ...
Active surveillance (“watch and wait”) functioned as a strategy to monitor biology while preserving sequencing flexibility for subsequent therapies. Living long-term with cancer means learning to live ...
Daiichi Sankyo announced that the first patient has been dosed in the global phase 3 TROPION-Lung17 trial. The study is evaluating DATROWAY in patients with locally advanced or metastatic nonsquamous ...
Induction Yervoy (ipilimumab) plus Opdivo (nivolumab) followed by consolidative chemoradiotherapy demonstrated bladder ...
The third and final day of the 2026 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium highlighted important developments in kidney cancer treatment, including combination ...
Day two of ASCO GU highlighted innovative therapies and the need for better quality-of-life reporting in genitourinary cancer trials. Dr. Eric Singer discusses rising early-onset kidney cancer, the ...
At 24 months overall survival was 62.8% with Welireg plus Lenvima versus 55.4% with Cabometyx. Median overall survival was 34 ...
Overall, day two of ASCO GU emphasized that advances in therapy must go hand-in-hand with patient-centered research. These ...
CURE ® readers have a unique opportunity each year to honor oncology nurses who have helped guide them through the cancer experience. Many thoughtful nomination essays are prepared and submitted by ...
At 7.3 years’ median follow-up, cabazitaxel failed to improve clinical PFS (62.8% vs 67.2%), metastasis-free survival, or overall survival versus androgen deprivation therapy plus radiotherapy.
Despite a trend toward more patient-centered research, quality-of-life end points remain substantially underreported in phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results